Drug trial results show that vaccines aren’t the only use for the mRNA technology behind the most widely used COVID-19 jabs. Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – .